Current studies into retatrutide, a dual agonist for GLP-1 and GIP receptors, are revealing encouraging outcomes in managing obesity and type 2 condition. Animal evidence suggest a distinct action contributing to https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/